Is Nivo/Ipi the Treatment of Choice for Patients with Advanced NSCLC, Tumor PD-L1 & lt;1%, & amp; High TMB? New Data from CheckMate 227 (BMIC-040)
Dr. Jack West reviews data from the CheckMate 227 trial in patients with advanced NSCLC & tumor PD-L1 <1% that suggests potential utility of the nivolumab/ipilimumab (nivo/ipi) combination in p...
Author: BeaconMedIC
Added: 06/21/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts